H.C. Wainwright raises Immix Biopharma price target to $25 By Investing.com
H.C. Wainwright has increased its price target for Immix Biopharma (NASDAQ:IMMX) to $25 from $20, reiterating a Buy rating, despite the company posting a wider net loss for Q2 2026 than previously estimated. The firm cited Immix's strong cash position of $234.2 million, providing …